Posts

Posted on

Birks Group Provides Business Update

Canada NewsWire

MONTREAL, Dec. 23, 2020 /CNW Telbec/ – Birks Group Inc. (the “Company” or “Birks Group”) (NYSE American: BGI), today provided a business update stating that as of December 23, 2020, 22 of the Company’s 29 stores across Canada are open and serving clients in accordance with the directives of local government and public health officials.

In accordance with current provincial restrictions to address the “second wave” of the COVID-19 pandemic, six of the Company’s Ontario stores, including its flagship Bloor Street store, and its Winnipeg store in Manitoba, have been temporarily closed for in-person shopping.  As a result of further provincial restrictions that were recently announced, required temporary closings for in-person shopping have been extended to all of the Company’s Ontario stores starting on December 26, 2020.  We currently expect the required closings to last until January 23, 2021. In addition, starting December 25, 2020, all Québec stores will be temporarily closed for in-person shopping until January 10, 2021. The Company’s remaining 13 stores in British Columbia, Alberta and Saskatchewan remain open for in-store shopping.

Birks Group expects that its revenue for the month of January 2021 will be negatively impacted by these stores closures and, as a result of these developments, the Company is implementing measures to mitigate the financial impact of these closures, including reducing operating expenses and extending payment terms with various stakeholders.

Curbside pick up will be available by appointment only at the following locations affected by the government restrictions:

Ontario

  • Maison Birks Downtown Toronto – Bloor Street
  • Maison Birks Yorkdale Shopping Centre
  • Maison Birks First Canadian Place
  • Maison Birks Sherway Gardens
  • Maison Birks Rideau Centre

Quebec

  • Maison Birks Sainte Catherine Street Montréal

“While some of our boutiques may be temporarily closed for in-store shopping, there are still a number of ways for clients to access Maison Birks’ elevated client service,” says Jean-Christophe Bédos, President and CEO of Birks Group. “Through our Concierge Service, virtual appointments and ecommerce, we are available for our clients and able to help them shop safely during this time. MaisonBirks.com is the #1 e-commerce destination in Canada for luxury watches and jewellery. We remain committed to, and recently invested in technological equipment for the purpose of, offering the highest possible quality in individual video shopping to our clients.”

Clients can make arrangements for curbside pickup through Maison Birks’ Concierge Service by phone at +1 (855) 873-7373 and email at [email protected]. Select boutiques are also offering virtual appointments, where clients can receive elevated service through video chat. Virtual appointments can be scheduled online at https://www.maisonbirks.com/en/virtual-appointment.

Clients can continue to shop online 24/7 at MaisonBirks.com and benefit from complimentary shipping across Canada

About Birks Group Inc.

Birks Group is a leading designer of fine jewellery, timepieces and gifts and operator of luxury jewellery stores in Canada. The Company operates 26 stores under the Maison Birks brand in most major metropolitan markets in Canada, one retail location in Calgary under the Brinkhaus brand, one retail location in Vancouver operated under the Graff brand and one location in Vancouver under the Patek Philippe brand. Bijoux Birks fine jewellery collections are also available through Mappin & Webb and Goldsmiths locations in the United Kingdom in addition to several jewellery retailers across North America. Birks was founded in 1879 and has become Canada’s premier retailer and designer of fine jewellery, timepieces and gifts. Additional information can be found on Birks’ web site, www.birks.com.

Forward Looking Statements

This press release contains certain “forward-looking” statements which can be identified by their use of words like “plans,” “expects,” “believes,” “will,” “anticipates,” “intends,” “projects,” “estimates,” “could,” “would,” “may,” “planned,” “goal,” and other words of similar meaning. All statements that address expectations, possibilities or projections about the future, including without limitation, statements about our strategies for growth, expansion plans, sources or adequacy of capital, expenditures and financial results are forward-looking statements.

Because such statements include various risks and uncertainties, actual results might differ materially from those projected in the forward-looking statements and no assurance can be given that the Company will meet the results projected in the forward looking statements. These risks and uncertainties include, but are not limited to the following: (i) the magnitude and length of economic disruption as a result of the worldwide COVID-19 outbreak, including its impact on (a) macroeconomic conditions, generally, (b) the results of operations and financial condition of the Company, (c) the Company’s revenue as a result of store closures and related measures to mitigate the financial impact of these closures, including reducing operating expenses and extending payment terms with various stakeholders, (d) capital investments in technology, and (e) the trading price of its shares; (ii) economic, political and market conditions, including the economies of Canada and the U.S., which could adversely affect the Company’s business, operating results or financial condition, including its revenue and profitability, through the impact of changes in the real estate markets, changes in the equity markets and decreases in consumer confidence and the related changes in consumer spending patterns, the impact on store traffic, tourism and sales; (iii) the impact of fluctuations in foreign exchange rates, increases in commodity prices and borrowing costs and their related impact on the Company’s costs and expenses; (iv) changes in interest rates; (v) the Company’s ability to maintain and obtain sufficient sources of liquidity to fund its operations, to achieve planned sales, gross margin and net income, to keep costs low, to implement its business strategy, maintain relationships with its primary vendors, to mitigate fluctuations in the availability and prices of the Company’s merchandise, to compete with other jewelers, to succeed in its marketing initiatives, and to have a successful customer service program; (vi) the Company’s ability to continue to borrow under its credit facilities, (vii) the Company’s ability to maintain profitable operations, as well as maintain specified excess availability levels under its credit facilities, make scheduled payments of principal and interest, and fund capital expenditures; (viii) the Company’s financial performance in the second half of fiscal 2021 and the level of capital expenditures requirements related to renewing store leases; (ix) the Company’s ability to execute its strategic vision; * the Company’s ability to continue as a going concern; and (xii) the Company’s ability to achieve compliance with the NYSE American’s continued listing standards within the required time frame. Information concerning factors that could cause actual results to differ materially is set forth under the captions “Risk Factors” and “Operating and Financial Review and Prospects” and elsewhere in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on July 8, 2020 and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

SOURCE Birks Group Inc.

Posted on

Birks Group Provides Business Update

Birks Group Provides Business Update

MONTREAL–(BUSINESS WIRE)–
Birks Group Inc. (the “Company” or “Birks Group”) (NYSE American: BGI), today provided a business update stating that as of December 23, 2020, 22 of the Company’s 29 stores across Canada are open and serving clients in accordance with the directives of local government and public health officials.

In accordance with current provincial restrictions to address the “second wave” of the COVID-19 pandemic, six of the Company’s Ontario stores, including its flagship Bloor Street store, and its Winnipeg store in Manitoba, have been temporarily closed for in-person shopping. As a result of further provincial restrictions that were recently announced, required temporary closings for in-person shopping have been extended to all of the Company’s Ontario stores starting on December 26, 2020. We currently expect the required closings to last until January 23, 2021. In addition, starting December 25, 2020, all Québec stores will be temporarily closed for in-person shopping until January 10, 2021. The Company’s remaining 13 stores in British Columbia, Alberta and Saskatchewan remain open for in-store shopping.

Birks Group expects that its revenue for the month of January 2021 will be negatively impacted by these stores closures and, as a result of these developments, the Company is implementing measures to mitigate the financial impact of these closures, including reducing operating expenses and extending payment terms with various stakeholders.

Curbside pick up will be available by appointment only at the following locations affected by the government restrictions:

Ontario

  • Maison Birks Downtown Toronto – Bloor Street
  • Maison Birks Yorkdale Shopping Centre
  • Maison Birks First Canadian Place
  • Maison Birks Sherway Gardens
  • Maison Birks Rideau Centre

Quebec

  • Maison Birks Sainte Catherine Street Montréal

“While some of our boutiques may be temporarily closed for in-store shopping, there are still a number of ways for clients to access Maison Birks’ elevated client service,” says Jean-Christophe Bédos, President and CEO of Birks Group. “Through our Concierge Service, virtual appointments and ecommerce, we are available for our clients and able to help them shop safely during this time. MaisonBirks.com is the #1 e-commerce destination in Canada for luxury watches and jewellery. We remain committed to, and recently invested in technological equipment for the purpose of, offering the highest possible quality in individual video shopping to our clients.”

Clients can make arrangements for curbside pickup through Maison Birks’ Concierge Service by phone at +1 (855) 873-7373 and email at [email protected]. Select boutiques are also offering virtual appointments, where clients can receive elevated service through video chat. Virtual appointments can be scheduled online at https://www.maisonbirks.com/en/virtual-appointment.

Clients can continue to shop online 24/7 at MaisonBirks.com and benefit from complimentary shipping across Canada

About Birks Group Inc.

Birks Group is a leading designer of fine jewellery, timepieces and gifts and operator of luxury jewellery stores in Canada. The Company operates 26 stores under the Maison Birks brand in most major metropolitan markets in Canada, one retail location in Calgary under the Brinkhaus brand, one retail location in Vancouver operated under the Graff brand and one location in Vancouver under the Patek Philippe brand. Bijoux Birks fine jewellery collections are also available through Mappin & Webb and Goldsmiths locations in the United Kingdom in addition to several jewellery retailers across North America. Birks was founded in 1879 and has become Canada’s premier retailer and designer of fine jewellery, timepieces and gifts. Additional information can be found on Birks’ web site, www.birks.com.

Forward Looking Statements

This press release contains certain “forward-looking” statements which can be identified by their use of words like “plans,” “expects,” “believes,” “will,” “anticipates,” “intends,” “projects,” “estimates,” “could,” “would,” “may,” “planned,” “goal,” and other words of similar meaning. All statements that address expectations, possibilities or projections about the future, including without limitation, statements about our strategies for growth, expansion plans, sources or adequacy of capital, expenditures and financial results are forward-looking statements.

Because such statements include various risks and uncertainties, actual results might differ materially from those projected in the forward-looking statements and no assurance can be given that the Company will meet the results projected in the forward looking statements. These risks and uncertainties include, but are not limited to the following: (i) the magnitude and length of economic disruption as a result of the worldwide COVID-19 outbreak, including its impact on (a) macroeconomic conditions, generally, (b) the results of operations and financial condition of the Company, (c) the Company’s revenue as a result of store closures and related measures to mitigate the financial impact of these closures, including reducing operating expenses and extending payment terms with various stakeholders, (d) capital investments in technology, and (e) the trading price of its shares; (ii) economic, political and market conditions, including the economies of Canada and the U.S., which could adversely affect the Company’s business, operating results or financial condition, including its revenue and profitability, through the impact of changes in the real estate markets, changes in the equity markets and decreases in consumer confidence and the related changes in consumer spending patterns, the impact on store traffic, tourism and sales; (iii) the impact of fluctuations in foreign exchange rates, increases in commodity prices and borrowing costs and their related impact on the Company’s costs and expenses; (iv) changes in interest rates; (v) the Company’s ability to maintain and obtain sufficient sources of liquidity to fund its operations, to achieve planned sales, gross margin and net income, to keep costs low, to implement its business strategy, maintain relationships with its primary vendors, to mitigate fluctuations in the availability and prices of the Company’s merchandise, to compete with other jewelers, to succeed in its marketing initiatives, and to have a successful customer service program; (vi) the Company’s ability to continue to borrow under its credit facilities, (vii) the Company’s ability to maintain profitable operations, as well as maintain specified excess availability levels under its credit facilities, make scheduled payments of principal and interest, and fund capital expenditures; (viii) the Company’s financial performance in the second half of fiscal 2021 and the level of capital expenditures requirements related to renewing store leases; (ix) the Company’s ability to execute its strategic vision; (x) the Company’s ability to continue as a going concern; and (xii) the Company’s ability to achieve compliance with the NYSE American’s continued listing standards within the required time frame. Information concerning factors that could cause actual results to differ materially is set forth under the captions “Risk Factors” and “Operating and Financial Review and Prospects” and elsewhere in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on July 8, 2020 and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Company Contacts:

Katia Fontana

Vice President and Chief Financial Officer

(514) 397-2592

For all press and media inquiries, please contact:

OverCat Communications

Audrey Hyams Romoff, [email protected], (647) 223-9970

Gillian DiCesare, [email protected], (647) 223-5590

Chelsea Brooks, [email protected], (289) 221-6006

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Online Retail Manufacturing Luxury Specialty Department Stores Women Fashion Men Other Manufacturing Retail Consumer

MEDIA:

Posted on

SHAREHOLDER ALERT: WeissLaw LLP Investigates Altimar Acquisition Corp.

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Altimar Acquisition Corp. (“ATAC” or the “Company”) (NYSE: ATAC) in connection with the Company’s proposed merger with privately-held alternative asset management firms Owl Rock Capital Group (“Owl Rock”) and Dyal Capital Partners (“Dyal Capital”).  Under the terms of the merger agreement, Owl Rock and Dyal Capital will combine and fold into ATAC, with ATAC acquiring the newly combined entity through a reverse merger that will result in the newly-combined entity becoming a public company traded on the New York Stock Exchange.  


If you own ATAC shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:


https://www.weisslawllp.com/ATAC/


Or please contact:



Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether ATAC’s board acted in the best interest of ATAC’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Dyal Capital and Owl Rock, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to ATAC public shareholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-altimar-acquisition-corp-301198318.html

SOURCE WeissLaw LLP

Posted on

ROSEN, RESPECTED INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against ACM Research, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – ACMR

NEW YORK, Dec. 23, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ACM Research, Inc. (NASDAQ: ACMR) between March 6, 2019 and October 7, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for ACM investors under the federal securities laws.

To join the ACM class action, go to http://www.rosenlegal.com/cases-register-2013.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company’s revenue and profits had been diverted to undisclosed related parties; (2) accordingly, the Company had materially overstated its revenues and profits; and (3) as a result, defendants’ statements about ACM’s business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2013.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com



Posted on

Shareholder Alert: Robbins LLP Announces That ACM Research, Inc. (ACMR) is Being Sued for Misleading Shareholders

Shareholder Alert: Robbins LLP Announces That ACM Research, Inc. (ACMR) is Being Sued for Misleading Shareholders

SAN DIEGO & FREMONT, Calif.–(BUSINESS WIRE)–
Shareholder rights law firm Robbins LLP announces that a purchaser of ACM Research, Inc. (NASDAQ: ACMR) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 6, 2019 and October 7, 2020. ACM Research, with its subsidiaries, develops, manufactures, and sells single-wafer wet cleaning equipment for enhancing the manufacturing process and yield for integrated chips worldwide.

If you suffered a loss due to ACM Research, Inc.’s misconduct, click here.

ACM Research, Inc. (ACMR) Misled Shareholders Regarding the Company’s Financial Prospects and Growth

According to the complaint, throughout the relevant period, defendants touted the Company’s financial profitability and growth in sales. However, these statements were false and misleading because defendants failed to disclose that the Company had diverted revenues and profits to undisclosed related parties and had materially overstated its revenues and profits.

On October 8, 2020, analyst J Capital Research published a report concluding that ACM Research “is a fraud, over-reporting both revenue and profit.” The report concluded that ACM Research’s revenue was overstated by 15-20% and claimed to have “evidence that undisclosed related parties are diverting revenue and profit from the company.” On this news, ACM Research’s stock declined $1.09 per share on October 8, 2020.

If you purchased your shares of ACM Research, Inc. (ACMR) between March 6, 2019 and October 7, 2020, you have until February 19, 2021, to ask the court to appoint you as lead plaintiff for the class.

Contact us to learn more:

Lauren Levi

(800) 350-6003

[email protected]

Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against ACM Research, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Lauren Levi

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]

(800) 350-6003

www.robbinsllp.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Triterras (TRIT) Investors with Losses to Contact Its Attorneys, Securities Fraud Case Filed

PR Newswire

SAN FRANCISCO, Dec. 23, 2020 /PRNewswire/ — Hagens Berman urges Triterras, Inc. (NASDAQ: TRIT) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

Class Period: August 20, 2020 – December 16, 2020
Lead Plaintiff Deadline: Feb. 19, 2021
Visit: www.hbsslaw.com/investor-fraud/TRIT
Contact An Attorney Now: [email protected] 
                                              844-916-0895

Triterras, Inc. (TRIT) Securities Class Action:

The complaint centers on the accuracy of Triterras’ and senior managements’ statements concerning the company’s dependence on- and the financial condition of- Rhodium Resources, a business controlled by Triterras CEO Srinivas Koneru.

More specifically, according to the complaint, Defendants made misleading statements about or concealed (1) the extent to which Triterras revenue growth depended on referrals from Rhodium, (2) Rhodium’s dire financial condition, and (3) that as a result Rhodium was likely to refer fewer users to the company.

Investors began to learn the truth, according to the complaint, on Dec. 17, 2020 when Triterras announced Rhodium was seeking a moratorium to shield itself from creditors while planning to restructure debts and continue business as a going concern.

This news sent the price of Triterras shares crashing lower.

“We’re focused on investors’ losses and proving Triterras intentionally misled them about the financial condition of its admitted material related party, Rhodium, when and after the company went public,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a Triterras investor and have significant losses, or have knowledge that may assist the firm’s investigation,  click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Triterras should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 844-916-0895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes is located at hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hagens-berman-national-trial-attorneys-encourages-triterras-trit-investors-with-losses-to-contact-its-attorneys-securities-fraud-case-filed-301198323.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

VANCOUVER, British Columbia, Dec. 23, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that the Company has elected to exercise its acceleration right under the warrant indenture (the “Indenture”) governing the common share purchase warrants of the Company (the “NovemberWarrants”) issued on November 1, 2019, Pursuant to the terms of the Indenture, the Company may accelerate the expiry date of the November Warrants when the daily volume-weighted average trading price (the “VWAP”) of the common shares of the Company (the “Common Shares”) exceeds $0.35 for the preceding 20 consecutive trading days on the Canadian Securities Exchange (the “CSE”).

As of the close of markets on December 11, 2020, the VWAP of the Common Shares on the CSE for 20 consecutive trading days has exceeded $0.35. Accordingly, the expiry date of the November Warrants is accelerated to January 21, 2021.

The Company announces that as of today’s date, there are approximately 6.5M November Warrants that have not yet been exercised.

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. Moreau

CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
[email protected]
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.


Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No securities regulatory authority or stock exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of the Offering, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

 



Posted on

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Restaurant Brands International Inc. – QSR

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Restaurant Brands International Inc. (NYSE: QSR) between April 29, 2019 and October 28, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Restaurant Brands investors under the federal securities laws.

To join the Restaurant Brands class action, go to http://www.rosenlegal.com/cases-register-1977.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Restaurant Brands’ “Winning Together Plan” was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (2) the “Tims Rewards” loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (3) as a result, defendants’ statements about Restaurant Brands’ business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1977.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq. 
      Phillip Kim, Esq. 
      The Rosen Law Firm, P.A. 
      275 Madison Avenue, 40th Floor 
      New York, NY 10016 
      Tel: (212) 686-1060 
      Toll Free: (866) 767-3653 
      Fax: (212) 202-3827 
      [email protected] 
      [email protected] 
      [email protected] 
      www.rosenlegal.com 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-globally-recognized-law-firm-announces-filing-of-securities-class-action-lawsuit-against-restaurant-brands-international-inc–qsr-301198190.html

SOURCE The Rosen Law Firm, P.A.

Posted on

Ventoux CCM Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering

PR Newswire

NEW YORK, Dec. 23, 2020 /PRNewswire/ — Ventoux CCM Acquisition Corp. (the “Company”) announced today that it priced its initial public offering of 15,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “VTAQU” beginning on December 24, 2020. Each unit consists of one share of common stock, par value $0.0001, one right and one redeemable warrant. Each right entitles the holder thereof to receive one-twentieth (1/20) of one share of common stock upon the consummation of an initial business combination. Each warrant entitles the holder thereof to purchase one-half of one share of common stock at a price of $11.50 per whole share. Once the securities comprising the units begin separate trading, the shares of common stock, rights and warrants are expected to trade on Nasdaq under the symbols “VTAQ,” “VTAQR” and “VTAQW,” respectively.

Chardan is acting as sole book-running manager of the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,250,000 units at the initial public offering price to cover over-allotments, if any.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 23, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Chardan, 17 State Street, 21st Floor, New York, New York 10004. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov.

About Ventoux CCM
Acquisition Corp.

Ventoux CCM Acquisition Corp. is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. While Ventoux CCM Acquisition Corp. may pursue an initial business combination in any region or sector, it intends to focus our efforts on businesses in North America within the hospitality, leisure, travel and dining sectors with an emphasis on consumer branded businesses that have attractive growth characteristics. In addition, Ventoux CCM Acquisition Corp. intends to pursue technology companies operating in these sectors, such as business and consumer services and infrastructure.

Forward Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements, including the successful consummation of the Company’s initial public offering, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Ed Scheetz

Chairman and CEO, Ventoux CCM Acquisition Corp.
[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/ventoux-ccm-acquisition-corp-announces-pricing-of-150-million-initial-public-offering-301198326.html

SOURCE Ventoux CCM Acquisition Corp.

Posted on

Ocugen Establishes Vaccine Scientific Advisory Board

Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine

MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) — Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multiple protein antigens of the virus.”

The vaccine scientific advisory board consists of:

  • Satish Chandran, PhD, Wyeth Vaccines, Pfizer, Nucleonics, Somahlution

    Dr. Chandran founded Somahlution and is currently the Somahlution’s Chief Executive Officer and a member of the Board of Directors since inception in 2010. Prior to Somahlution he was the Chief Technology Officer at Pfizer Biotherapeutics and prior to that was the COO and CSO of Nucleonics, Inc. Satish started his biotech career at Apollon, Inc., headed the DNA vaccines at Wyeth Vaccines. He is a biotechnology veteran with nearly 30 years of leadership positions. Over the last 30 years, his career in biological research and development has spanned across academia and industry; early start up and mid-stage biotech companies and in large pharmaceutical companies. Satish’s passion and strength are in building and assembling teams and taking novel concepts and therapeutic strategies into products through development, regulatory approval, and commercialization. He is currently on the Board of Directors and serves as scientific advisor and consultant to several biotechnology companies.
  • David Fajgenbaum, MD, MBA, MSc, FCPP, Translational Medicine & Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment & Laboratory

    Dr. Fajgenbaum is an Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, Director of the Penn Center for Cytokine Storm Treatment & Laboratory, Executive Director of the Castleman Disease Collaborative Network, and Associate Director, Patient Impact for the Penn Orphan Disease Center. He is doing groundbreaking work to advance precision medicine for Castleman disease, a condition that he is battling as a physician, researcher, advocate, and patient. Combining omic technologies with machine learning and other bioinformatic tools, Dr. Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others. Now, he is spreading this approach to other diseases such as COVID19.
  • Bruce Forrest, MB, BS, MD, MBA, Wyeth Vaccines, Pfizer

    For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&D CMC and Manufacturing activities. In addition, Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield® (EU), Prevnar® (Global), and FluMist®. Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.).

  • Catherine Pachuk, PhD, Chief Scientific Officer, Marizyme, Wyeth Vaccines, Pfizer and Coronavirologist, Vaccinologist

    Dr. Pachuk has over twenty-five years R&D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device, and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC, and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals.

  • Harvey Rubin, MD, PhD, Professor of Microbiology and Infectious Diseases, U Pennsylvania

    Dr. Rubin is Professor of Medicine with secondary appointment as Professor of Computer Sciences at the University of Pennsylvania. The NIH, NSF, DARPA, the Global Alliance for TB Drug Discovery, and the Gates Foundation have funded his basic biochemical and genetic research in infectious diseases, resulting in more than 100 peer-reviewed papers. He served on national and international scientific review panels including the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the U.S. National Science Advisory Board for Biosecurity and the Dept. of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. Dr. Rubin is the founder of Energize the Chain, a non-profit organization and GAVI INFUSE and funded partner that ensures the delivery of vaccines to people in the most remote regions of the world by utilizing power and connectivity in the private sector, such as that available at cell tower sites to power the refrigeration systems that are necessary to keep vaccines at the proper temperature.

  • Susan Weiss, PhD, Professor of Microbiology, U Pennsylvania. Co-Director Coronavirus Research Center and Renowned Coronavirologist

    Dr. Weiss obtained her PhD in Microbiology and Molecular Genetics from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco with Mike Bishop and Harold Varmus. She moved to the University of Pennsylvania in 1980, where she is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:

Ocugen, Inc.

Sanjay Subramanian
Chief Financial Officer
[email protected]

Media Contact:
LaVoieHealthScience
Lisa DeScenza
[email protected]
+1 978-395-5970